Pravastatin for Prevention of Preeclampsia

Inclusion Criteria: Documented history (review of chart or delivery note) of prior severe early onset PE in a prior pregnancy and requiring delivery ≤340/7 weeks' gestation. If in the index pregnancy, the woman was induced at the upper limit of 34 0/7 weeks of pregnancy and delivered within 48 hours in the same hospitalization, that woman could be enrolled. Women with severe PE in a pregnancy remote (greater than 2 pregnancies removed) from the current pregnancy do not qualify. * 18 years or older with the ability to give informed consent * Singleton pregnancy * Normal serum transaminase (ALT and AST) concentrations in the last 6-months * Gestational age (GA) between 12 weeks 0 days to 16 weeks 6 days based on clinical information and confirmed by an ultrasound per study procedures. * Willingness to participate in planned PK study visits Exclusion Criteria: Known chromosomal, genetic, or major fetal malformations, fetal demise, or planned termination * Patients with contraindications for statin therapy: * Hypersensitivity to pravastatin or any component of the product * Active liver disease (acute hepatitis, chronic active hepatitis, persistently abnormal liver enzymes (2 x normal of serum transaminases) * History of myopathy or rhabdomyolysis * Patients with any of the following conditions: * HIV positive * Status post solid organ transplant * Chronic renal disease/insufficiency with baseline serum creatinine ≥1.5 mg/dL * Uterine malformations (didelphus, bicornuate, un…